InnoSIGN offers its OncoSIGNal technology to gain insight into the functional activity of cellular signaling pathways. mRNA levels transcribed from direct target genes regulated by the pathway transcription factors are translated into pathway activity scores for the ER, AR, PI3K, MAPK, Hedgehog, TGFbeta, Notch, Wnt, NFkB and JAK-STAT1/2 pathways, resulting in a quantitative characterization of the cell molecular phenotype. OncoSIGNal is available for clinical use in breast cancer as a lab-developed test through InnoSIGN’s CLIA laboratory in Mason (OH), for research use through labs in the EU and US as a comprehensive testing service, or as a distributed PCR kit for use in a customer laboratory. The analysis can also be run from RNA-seq data for various cancer and cell types. InnoSIGN utilizes its extensive database with more than 100,000 pathway activity profiles to support drug and diagnostics development.